Article

2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



@@#116300@@

Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mardi 5 novembre 2019
Doi : 10.1016/j.jaad.2019.07.070
accepted : 23 July 2019
Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts
 

Ahmad Nofal, MD a, , Ayman Marei, MD, PhD b, Al-shimaa M. Ibrahim, MD a, Eman Nofal, MD a, Manal Nabil, MSc a
a Dermatology Department, Zagazig University, Zagazig, Egypt 
b Microbiology and Immunology Department, Zagazig University, Zagazig, Egypt 

Correspondence to: Ahmad Nofal, MD, Dermatology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.Dermatology DepartmentFaculty of MedicineZagazig UniversityZagazigEgypt
Abstract
Background

Despite the availability of different therapeutic modalities, treatment of recalcitrant common warts is still challenging. Cervarix (GlaxoSmithKline, Brentford, UK), a recombinant bivalent human papillomavirus (HPV) vaccine, has shown promising efficacy in the treatment of warts.

Objectives

To evaluate the beneficial effects and tolerability of intramuscular versus intralesional bivalent HPV vaccine in the treatment of recalcitrant common warts.

Methods

The study included 44 adult patients with multiple recalcitrant common warts; 22 patients received intramuscular injection of bivalent HPV vaccine at 0, 1, and 6 months or until complete clearance of warts, and the other 22 patients received intralesional injection of 0.1 to 0.3 mL of bivalent HPV vaccine into the largest wart at 2-week intervals until complete clearance or for a maximum of 6 sessions.

Results

Complete clearance of warts was observed in 18 patients (81.8%) of the intralesional group and 14 patients (63.3%) of the intramuscular group; however, the difference was not statistically significant. Adverse effects were transient and insignificant, and no recurrence was reported in either group.

Limitations

Small study sample and different dosing schedules.

Conclusions

Bivalent HPV vaccine, particularly by intralesional injection, seems to be a potential therapeutic option for the treatment of multiple recalcitrant common warts.

The full text of this article is available in PDF format.

Key words : bivalent HPV vaccine, HPV vaccines, recalcitrant warts

Abbreviation used : IL



 Funding sources: None.
 Conflicts of interest: None disclosed.
 Reprints not available from the authors.



© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline